By the PharmaTradz BD Team. Published October 2026.
On 11 August 2026, the US Food and Drug Administration proposed making GRAS notification mandatory. Today a company can decide for itself that a food ingredient is "generally recognised as safe" and sell it without telling the agency. Under the proposal, it would have to notify FDA and file its evidence. Comments are open until 9 December 2026. If you make or export ingredients for the US food or supplement market, or buy them for a private-label range, this is the time to get your paperwork in order.
What GRAS is and why the change matters
US law treats any substance added to food as a food additive that needs FDA approval, unless qualified experts generally recognise it as safe for its intended use. That exception is GRAS. Companies have long been able to reach their own GRAS conclusion, often called self-affirmed GRAS. Since 1997, they have been able to choose whether to send it to FDA through a voluntary notification programme.
Self-affirmation became popular for two reasons: it is faster than waiting for an agency review, and it keeps safety data confidential. The proposed rule would end the "silent" version. The safety conclusion would still be the company's, but FDA would see the basis for it.
The global angle is significant. FDA's own figures show that, by March 2025, its food centre had received more than 1,200 GRAS notices, and 617 of them came from firms outside the United States. Ingredient makers in Europe, Asia and Latin America are already part of this system and would be directly affected by the change.
What the proposed rule would require
- Mandatory notice. Anyone introducing a substance into US interstate commerce on the basis of a GRAS conclusion would have to notify FDA, unless an exception applies. The rule covers human and animal food, including food-contact substances such as packaging materials.
- Notification, not approval. A company could keep selling while FDA reviews the notice. But the notice only counts once FDA has formally filed it.
- Review time. FDA would aim to respond within 180 days of filing, with up to two 90-day extensions. The outcome would be a "no questions" letter, a letter saying the basis is insufficient, or a letter confirming it has stopped evaluating the notice at the company's request.
- Electronic filing in English. Notices would go through FDA's online submission system, and foreign-language documents would need English translations.
- Consequences. Failing to notify would not by itself make an ingredient unlawful, but FDA says it may take non-compliance into account when choosing what to review after an ingredient is on the market.
The proposed timeline
| Step | Proposed timing |
|---|---|
| Proposal published | 11 August 2026 |
| Public comments close | 9 December 2026 |
| Final rule | Not yet scheduled |
| Rule takes effect | 60 days after the final rule is published |
| Streamlined listing for ingredients already on the market | Within one year of the effective date |
| Mandatory notification applies | 18 months after the effective date |
In practice, nothing changes tomorrow. Even if the rule is finalised in 2027, the main obligation would not apply until well after that. The value of acting now lies in preparation, not in rushing to file.
Who would not need to notify
The proposal lists several exceptions. The ones most relevant to ingredient suppliers are:
- uses already covered by an FDA "no questions" letter;
- substances listed or affirmed as GRAS in FDA's regulations (21 CFR parts 182, 184 and 186);
- substances under a threshold-of-regulation exemption, which the rule would extend;
- substances placed on FDA's public list through the one-time streamlined submission.
The streamlined submission is meant for ingredients already sold in the US before the rule takes effect. It asks for basic information rather than a full safety dossier: who you are, what the substance is, how it is used and evidence that it was already in US commerce. It is not available for a substance that has received an "insufficient basis" letter. FDA can still ask questions later or ask for a full notice.
What it means for dietary supplements
Supplements sit under a separate framework. A new dietary ingredient generally needs its own notification (an NDI notification) before it is sold in a supplement. GRAS status for food use does not settle the NDI question for supplement use, and the reverse is also true. Each use has to be assessed on its own terms.
That said, many supplement ingredients have relied on self-affirmed GRAS, often to establish a food use first. Supplement trade bodies have said they will comment on the proposal, and some have warned that mandatory review could create a backlog the agency is not resourced to clear. If you sell into the US supplement market, check both routes for each ingredient: its GRAS basis and its NDI position.
Why the final rule may look different
Several open questions could change the outcome:
- Legal authority. In 2016, FDA said it lacked express statutory authority to require GRAS notices. Lawyers expect a challenge if the rule is finalised.
- Agency capacity. Mandatory notices could mean hundreds, possibly thousands, of new submissions.
- Confidentiality. Companies are concerned about how much safety data competitors could see.
- State laws. Several US states are working on their own GRAS-reporting bills, and the federal proposal would not override them.
What ingredient suppliers and brands should do now
| Action | Why |
|---|---|
| List every ingredient you sell into the US and its regulatory basis | You need to know which ones rely on self-affirmed GRAS |
| Check for "no questions" letters and 21 CFR listings | These are likely to be exempt |
| Keep proof of US sales: invoices, shipping and customs records | The streamlined route requires evidence of earlier commerce |
| Locate your GRAS dossier and expert panel report, and update them | A weak or missing dossier is the biggest risk once FDA sees it |
| Agree who files: the ingredient maker or the brand | The proposal does not say; settle it in your supply contract |
| For supplements, confirm the NDI position separately | GRAS for food use does not cover supplement use |
| Prepare English translations of key documents | Foreign-language material would need translation |
| Consider commenting by 9 December 2026 | The final shape of the rule is still open |
If you are a brand sourcing private-label products, add these questions to your supplier checks now. Ask each ingredient supplier how they reached their GRAS conclusion, whether FDA has seen it and who will file if the rule goes ahead. A supplier with a clear answer and an organised dossier is a safer long-term partner.
How PharmaTradz can help
We work with nutraceutical and food-ingredient buyers who need manufacturers with sound documentation for the US and other regulated markets. Our private-label nutraceutical buyer's guide covers what to check before you choose a manufacturer, and our nutraceutical sourcing service can help you compare suppliers. To get started, send us a sourcing request with your ingredient list and target markets.
This article summarises a proposed rule as of October 2026. It is not legal advice; please speak to qualified regulatory counsel about your own products.
Frequently Asked Questions(FAQs)
What is self-affirmed GRAS?
It is when a company, usually with an independent expert panel, concludes on its own that a food ingredient is generally recognised as safe for its intended use and sells it without notifying FDA. The proposed rule would require that conclusion to be notified to FDA.
When would mandatory GRAS notification start?
Not yet. The proposal was published on 11 August 2026 and comments close on 9 December 2026. If finalised, the rule would take effect 60 days after publication, and the notification requirement would apply 18 months after that.
Does the GRAS rule apply to dietary supplements?
The rule covers human and animal food. Supplement ingredients follow the separate new dietary ingredient (NDI) process, and GRAS status for food use does not settle NDI status. Many supplement ingredients have relied on self-affirmed GRAS, though, so suppliers should check both routes.
What happens to ingredients already on the US market?
The proposal offers a one-time streamlined submission, due within a year of the rule taking effect, for substances already in US commerce. It asks for basic information and evidence of earlier sales rather than a full safety dossier.
Does the rule affect suppliers outside the United States?
Yes. It applies to anyone introducing a substance into US interstate commerce on a GRAS basis. Foreign firms already file a large share of GRAS notices, and foreign-language documents would need English translations.
